Vertex Pharmaceuticals (NASDAQ:VRTX)

Vertex Scores Key Analyst Upgrade on Top of Making an Acquisition

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) has seen a lot of choppy trading in 2019, rising from about $164 at the start of the year to near $195 during the first ...
Read Full Story »

Vertex Pharmaceuticals and Other Biotech Stocks With Recent Golden Crosses

Golden crosses and death crosses are common signals in technical analysis and refer to the relationship between short-term and long-term moving averages. The golden cross typically is seen as a ...
Read Full Story »

Citigroup Sees Big Upside for 2 of the Largest Biotechs

After quite some time of muted or negative performance, big biotech may be worth a look again. Citigroup analyst Mohit Bansal assumed coverage of the large-cap biotech space and sees ...
Read Full Story »

Tuesday’s Top Analyst Upgrades and Downgrades: Tesla, Uber, Amgen, Biogen, Gilead, Deckers, Vertex Pharma, KKR and More

Although the broad markets have been in a slump recently amid China trade talks, the S&P 500 and Dow futures for Tuesday morning were relatively positive. While there has been ...
Read Full Story »

What CRISPR Has Planned for Transfusion-Dependent Beta Thalassemia

When CRISPR Therapeutics A.G. (NASDAQ: CRSP) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CTX001 for the treatment of transfusion-dependent beta thalassemia, its ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Alcoa, Apple, Autodesk, BB&T, Bed Bath & Beyond, Camping World, Nvidia, Vertex, Voya and More

Stocks were indicated to open higher on Tuesday as bond yields appear to be stabilizing after the yield curve inverted late last week. Investors need to consider how they want ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Boeing, Booking, Camping World, Domino’s, iRobot, MetLife, Neogen, Southern Copper, Vertex, Worldpay and More

Stocks were indicated to open higher on Tuesday morning after Monday's gains. With the market having recovered so much in 2019, investors have to be considering how they want their ...
Read Full Story »

Major Biopharma Catalysts Coming in the First Quarter of 2019

Biotech and pharmaceutical companies generally are involved in the lengthy process of getting their drug candidates to market through clinical trials. The amount of risk involved ranges from fair to ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Aflac, Akamai, BioMarin, Caesars Entertainment, CBS, Crocs, GW Pharma, Medtronic, Netflix, Sirius XM and More

Stocks entered the new year on a sour note, with equity futures down about 1.5% after weaker Chinese economic data. While investors used to buy every sell-off, the volatility in ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Apple, Baker Hughes, Biogen, FedEx, Intel, Micron, Roku, Shake Shack and More

Stocks were in the middle of their worst December since the Great Depression, but Tuesday's small recovery was followed by some additional stock gains on Wednesday. The market is hoping ...
Read Full Story »

5 Merrill Lynch US 1 Health Care Stocks Could Be Big 2019 Winners

With just over six weeks left in what has been a very volatile 2018, many investors are wondering which direction the market will take now that Democrats are taking over ...
Read Full Story »

CRISPR Wins FDA Approval for Human Trials

CRISPR Therapeutics A.G. (NASDAQ: CRSP) shares made a handy gain on Thursday after the company announced a key U.S. Food and Drug Administration (FDA) decision concerning its collaboration with Vertex ...
Read Full Story »

Merrill Lynch Loves Large Cap Biotech: 4 Top Stocks to Buy Now

More and more, the companies that we cover on Wall Street are starting to agree that while the future's still bright for the U.S. economy, it may be one of ...
Read Full Story »

Stifel Has Red-Hot Biotech Stocks to Buy With Huge Upside Potential

Needless to say, the biotech world has had a volatile 18 months. Some of the biggest and the best companies, many of which trade cheaper than big pharmaceutical companies, are ...
Read Full Story »

Vertex Wins FDA Approval for Expanded Cystic Fibrosis Treatment

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares saw a handy gain on Thursday after the U.S. Food and Drug Administration (FDA) gave the nod to Vertex’s cystic fibrosis (CF) treatment. Essentially, ...
Read Full Story »